Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.